Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D02003 (
NBT
)
1,323
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It was shown that the functional state of neutrophils and monocytes in the peripheral blood of patients with sarcoidosis lowered which was evident from their lower absorbing capacity, lower numbers of the
EAC
-rosette-forming cells and higher metabolic activity. Prior prednisolone therapy influenced the functional state of neutrophils: the cell ability to reduce
NBT
and the activity of acid phosphatase decreased while the lysozyme levels and absorption capacity increased. The functional state of monocytes was in general the same in the patients treated and untreated with the glucocorticoid.
...
PMID:[The effect of hormonal therapy on the functioning of phagocytosing blood cells in patients with sarcoidosis]. 258 51
In a study carried out in a group of 61 pregnant women in the 21st to the 41st week of gestation and comparatively in 9 nonpregnant controls, the following were determined: changes in the leukocyte and lymphocyte count, proportion of T cell rosettes, T1 rosettes (TM cells), T2 rosettes (TG cells),
EAC
rosettes (B cells), EACD rosettes (killer cells), circulating
NBT
-positive phagocytes, serum IgG, IgA, IgM and C3 concentrations, 50% hemolytic activity of the complement system. The results are interpreted in the light of present data regarding the mechanisms of ovo-embryo-fetal allograft.
...
PMID:Immunologic alterations in the third trimester of pregnancy. 311 65
The effects are reported of a combination therapy of i.v. C. parvum and cyclophosphamide on the survival time and immune responses of patients with inoperable squamous-cell carcinoma of the bronchus. The immune status of the patients was evaluated by determining the antibody response to C. parvum, the E and
EAC
rosettes, the PHA response of blood lymphocytes, the skin-test reactivity to Candida and PPD, the response to DNCB and the chemotaxis and
NBT
-dye reduction capacity of neutrophil leucocytes. The survival time of patients treated with the combination therapy was found to be significantly shorter than that of untreated patients and of those receiving cyclophosphamide only. Severe side effects were observed after C. parvum infusions, with no decrease on repeated administration. The effect of C. parvum on the different immune parameters of cyclophosphamide-treated patients was negligible, though there was a normal antibody response to C. parvum.
...
PMID:Harmful effects of i.v. Corynebacterium Parvum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus. 738 58
In 10 patients with chronic renal failure treated with haemodialyses (HD) T and B cell populations were determined in peripheral blood, together with immunoglobulin concentration and
NBT
test in the first two hours of the procedure using cuprophan and cellulose acetate dialysers. It was found that the per cent proportions of T4, T8 and T11 were not significantly changed. The proportions of B cells with sIg, sIgG, sIgM, sIgA were not significantly altered during HD with cuprophan dialysers. The per cent of B cells with sIg, sIgG decreased significantly during HD with cellulose acetate dialysers. The per cent proportions of active and late E rosettes decreased significantly, the per cent of stable E rosettes rose significantly, while that of
EAC
rosettes was not significantly changed in the initial HD period with the use of both dialyser types. IgG concentration rose significantly in the initial period of HD with either dialyser, while there was no significant change in the concentration of IgA and IgM. The value of the
NBT
test was not altered significantly during HD with either dialyser type.
...
PMID:[Subpopulations of t and B lymphocytes, rosette tests, levels of immunoglobulins in peripheral blood and NBT test in the initial period of hemodialysis conducted with cuprophan or cellulose acetate dialysers in patients with chronic renal failure]. 781 71